Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002197 · ClinicalTrials.gov registry record · NA
A Study of 1592U89 in HIV-Infected Children
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
- 250
- Enrollment target
NCT00002197 is a NA study that has completed, run by Glaxo Wellcome. The registered enrollment target is 250 participants.
The verdict
NCT00002197, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe to give 1592U89 to children (aged 6 months until 14th birthday) with advanced HIV infection who have few treatment options available. The study also examines the effect 1592U89 has on the levels of HIV in the blood.
Interventions
- DRUG Abacavir sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002197
The ClinicalTrials.gov registry entry for NCT00002197 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Abacavir sulfate is the first listed.
NCT00002197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002197 about?
NCT00002197 is a clinical study titled "A Study of 1592U89 in HIV-Infected Children". The purpose of this study is to see if it is safe to give 1592U89 to children (aged 6 months until 14th birthday) with advanced HIV infection who have few treatment options available. The study also examines the effect 1592U89 has on the levels of HIV in the blood.
What is the current status of trial NCT00002197?
This trial is currently completed. It is a NA study. The enrollment target is 250 participants.
What interventions are being tested in trial NCT00002197?
The interventions under investigation include: Abacavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00002197?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.